Drugs / Octafibrin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01575756 | Jun 2013 → Jan 2015 | congenital afibrinogenemia | Octapharma | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02408484 | Dec 2015 → Jun 2019 | congenital fibrinogen deficiency | Octapharma | Completed | No outcome recorded |
| Phase 3 | NCT02267226 | Sep 2014 → Feb 2018 | congenital fibrinogen deficiency | Octapharma | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03037424 Comparator | Feb 2017 → Nov 2018 | acquired coagulation factor deficiency | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Octafibrin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02408484 ↗ |
| Known as | Fibryga | “fibrinogen concentrate (Octafibrin/Fibryga; Octapharma) is non-inferior to cryoprecipitate” PMID 29678987 ↗ Apr 2018 |
| Modality | Protein / enzyme biologic | “Plasma derived fibrinogen concentrate” NCT01575756 ↗ |
| Route | Intravenous | “Octafibrin 70 mg/kg intravenously once” NCT01575756 ↗ |